BrainsWay is an industry leader in the field of transcranial magnetic stimulation (TMS). BrainsWayâs flagship Deep TMS technology is a non-invasive, well-tolerated outpatient treatment, clinically proven to treat psychiatric and neurological conditions. BrainsWay has received FDA-clearance for both major depression (MDD) and obsessive compulsive disorder (OCD- De Novo) and is developing more applications outside of the US. The company also has approval in Japan and other Asian countries. BrainsWay continues to push the TMS envelope with multiple clinical studies and further research into novel indications. BrainsWay has an experienced business and development management team, as well as the backing of key scientific opinion leaders. BrainsWay was founded in 2003 and began trading on the NASDAQ in 2019 under the symbol BWAY. Source
No articles found.
Avenue Therapeutics, Inc., a Fortress Biotech (NASDAQ: FBIO) Company, is a special...
Avenue Therapeutics, Inc., a Fortress Biotech (...
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed st...
Momenta Pharmaceuticals is a biotechnology comp...
Alseres Pharmaceuticals, Inc. is focused on the development of diagnostic and ther...
Alseres Pharmaceuticals, Inc. is focused on the...
Soliton, Inc. is a medical device company with a novel and proprietary platform te...
Soliton, Inc. is a medical device company with ...
Intellia Therapeutics is a leading genome editing company focused on developing cu...
Intellia Therapeutics is a leading genome editi...
RTI Surgical Holdings, Inc. is a leading global surgical implant company providing...
RTI Surgical Holdings, Inc. is a leading global...
Neuronetics, Inc. is focused on designing, developing, and marketing products that...
Neuronetics, Inc. is focused on designing, deve...
Join the National Investor Network and get the latest information with your interests in mind.